- Home
- ASO vs ICUI Comparison
ASO vs ICUI Comparison
Compare ASO & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASO | ICUI |
|---|---|---|
| Founded | 1938 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.2B |
| IPO Year | 2020 | 1992 |
Fundamental Metrics
Financial Performance| Metric | ASO | ICUI |
|---|---|---|
| Price | $51.58 | $148.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 5 |
| Target Price | $59.06 | ★ $179.50 |
| AVG Volume (30 Days) | ★ 2.0M | 255.7K |
| Earning Date | 12-09-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.97% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.48 | N/A |
| Revenue | ★ $6,011,862,000.00 | $2,320,363,000.00 |
| Revenue This Year | $4.05 | N/A |
| Revenue Next Year | $6.32 | N/A |
| P/E Ratio | $9.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $33.34 | $107.00 |
| 52 Week High | $61.25 | $175.51 |
Technical Indicators
Market Signals| Indicator | ASO | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 61.40 |
| Support Level | $53.15 | $141.39 |
| Resistance Level | $55.53 | $148.95 |
| Average True Range (ATR) | 2.08 | 3.95 |
| MACD | 0.05 | -0.58 |
| Stochastic Oscillator | 39.59 | 75.83 |
Price Performance
Historical ComparisonAbout ASO Academy Sports and Outdoors Inc.
Academy Sports and Outdoors Inc is engaged in the full-line sporting goods and outdoor recreation retailer in the United States. The company's product categories are outdoors, apparel, sports & recreation, and footwear.
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.